Company intelligence / Profile preview

Dragon Boat Biopharmaceutical

Shanghai, China

Ownership: Private
Development stage: Other

Overview

Dragon Boat Biopharmaceutical has a pipeline of 9 biologics candidates with 4 in clinical development. Notable programs include BC003 (anti-PD-L1) in Phase 2 for non-clear cell renal cell carcinoma and nasopharyngeal carcinoma showing ORR of 26.7% in nasopharyngeal carcinoma; BC001 (anti-EGFR) showing Phase Ib efficacy of ORR 94.1% in penile cancer combination therapy; BC008 (anti-CLDN18.2) approved for clinical trials in advanced solid tumors; and BC007 (bispecific anti-CLDN18.2/CD47) with NMPA IND acceptance showing dose-dependent anti-tumor effects in preclinical studies.

Therapeutic areas: OncologyImmunologyPulmonologyDermatology
Modalities: Monoclonal antibodyBispecific monoclonal antibodyNanobody therapyAntibody
Industry: Biotech

Partnerships

AdageneSanyou Biopharmaceuticals

Beyond the preview

Go deeper on Dragon Boat Biopharmaceutical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Dragon Boat Biopharmaceutical.

Explore the full profile